|
Founding Partner of the Millennix division, which is focused in oncology, immunology, gene therapy, vaccines, complex infectious diseases, metabolic disease and other chronic indications. Dr. Resnick is an executive and physician with extensive senior management experience in drug development, contract clinical research and clinical medicine, demonstrating success in a broad range of therapeutics. He directs Millennix activity in strategic planning, clinical study development, regulatory representation and medical/safety monitoring. Dr. Resnick was previously Vice President, Clinical Research Oncology, at the Schering-Plough Research Institute (1992-1997) where he was responsible for all domestic and international Phase I - III clinical research projects in oncology, including development of 12 small molecules, biologics, cytokines and gene therapy products. He participated in multiple IND/NDA filings, and led the multi-disciplinary oncology product licensing and collaboration development. In addition, he was Vice President, Medical Affairs at In Vivo, Inc. (1989-1992), where he was instrumental in expanding Company activities from Phase IV into pivotal Phase I-III clinical trials. He acted as liaison to pharmaceutical/biotech sponsors’ clinical, scientific, and medical-marketing staff, and provided expert, FDA-compliant medical monitor function. With clinical experience in Internal Medicine and Hematology/Oncology at New York Hospital-Cornell Medical Center (1979-1989) as Assistant Attending Physician, Dr. Resnick provided medical care to 2,000 patients, and fulfilled teaching and research duties at Cornell Medical Center. He also was a NCI cooperative group study chairman. Dr. Resnick is a Diplomate, Medical Oncology and Internal Medicine, American Board of Internal Medicine, and a Diplomate, National Board of Medical Examiners. He received his BS (1970) from Cornell University, and his MD (1974) from Cornell University Medical College. Dr. Resnick has had numerous scientific publications, and made many presentations at scientific symposia, the FDA, international regulatory authorities and industry organizations. | 